Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination regimen consisting of three components: - **Folic acid** (a synthetic form of vitamin B9) is essential for DNA synthesis and repair, red blood cell formation, and prevention of anemia. - **Proguanil** (marketed as Paludrine) is an antimalarial agent that acts as a prodrug; its active metabolite cycloguanil inhibits the malaria parasite's dihydrofolate reductase, disrupting folate metabolism in the parasite and preventing its replication[4][6][9]. - **Jobelyn** is a proprietary extract derived from Sorghum bicolor. It has been studied for its antioxidant properties and potential to improve hematological parameters such as hemoglobin levels. It may also have anti-inflammatory effects[1][3][7]. This combination has been used in clinical studies involving patients with sickle cell anemia to support hematopoiesis, prevent malaria (especially in endemic regions), and provide antioxidant benefits[1][7]. Folic acid supplementation is particularly important when using proguanil due to possible depletion of body stores by the drug[4]. Jobelyn may further contribute to improved hemoglobin levels and immune function through its phytochemical content[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on folic acid + proguanil + Jobelyn.